SCHEMBL1807254

SCHEMBL1807254

NC(=O)c1ccc(-c2csc(SCC(=O)NCC3CN(Cc4ccc(F)c(F)c4)CCO3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.48
ALDH1A1 P00352 6/20 0.44
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RAB9A P51151 3/20 0.40
MCHR1 Q99705 1/20 0.40
DRD4 P21917 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
POLB P06746 3/20 0.38
NPC1 O15118 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
MAPT P10636 1/20 0.38
GRM2 Q14416 3/20 0.37
KCNH2 Q12809 2/20 0.37
NR1I2 O75469 1/20 0.37
HPGD P15428 2/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807258 1.00 CCR3 (0.48) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1807520 0.94 ALDH1A1 (0.46) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1807515 0.94 ALDH1A1 (0.46) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1809196 0.92 ALDH1A1 (0.43) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1809194 0.92 ALDH1A1 (0.43) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1810625 0.91 CCR3 (0.60) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1810622 0.91 CCR3 (0.60) CCR3ALDH1A1MEN1KMT2ARAB9A
SCHEMBL1807191 0.89 ALDH1A1 (0.48) CCR3ALDH1A1MEN1KMT2AMCHR1
SCHEMBL1807196 0.89 ALDH1A1 (0.48) CCR3ALDH1A1MEN1KMT2AMCHR1
SCHEMBL1807785 0.85 ALDH1A1 (0.46) CCR3ALDH1A1MEN1KMT2AMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 CCR3 1/4885ALDH1A1 2661/4885MEN1 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.